Ad blocking detected

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.


Canada NewsWire

  • Q4-2022 revenue guidance raised to a record $12.5M - $13.0M
  • Fiscal 2022 revenue guidance increased to a record $27.5M - $28.0M

MONTREAL, Nov. 15, 2022 /CNW Telbec/ - Valeo Pharma Inc. (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company") a Canadian pharmaceutical company, today announced that it has raised revenue guidance for its fourth quarter of 2022 to $12.5 - $13.0 million, an increase of 14% to 18% over previously issued guidance of $11 million. The Company is also increasing its fiscal 2022 revenue guidance to $27.5 – 28.0 million, a forecasted increase exceeding 100% compared to fiscal 2021 revenues of $13.6 million.

The quarterly and yearly revenue increases result from the continued growth of the two innovative asthma therapies Enerzair® Breezhaler® and Atectura® Breezhaler® and the low molecular weight heparin biosimilar REDESCA™, as well as the  additional revenues generated in the fourth quarter by the recently added ophthalmology products XIIDRA®, SIMBRINZA®, and the epinephrine auto-injector ALLERJECT®.

"Our lead products have delivered the strong growth we forecasted for 2022. With a first full year of commercial activities for Enerzair and Atectura now completed,  both products are generating strong sequential quarterly  increases in the number of total prescribers, total prescriptions and revenues", said Steve Saviuk, CEO. "The recent addition of our ophthalmic and severe allergy products in early August materially impacted our fourth quarter  and we expect them to significantly contribute to our overall 2023 revenues as well".   

About Valeo Pharma Inc.

Valeo Pharma is a fast growing pharmaceutical company dedicated to the commercialization of innovative prescription products in Canada with a focus on Respirology/Allergy, Ophthalmology and Specialty Products. Headquartered in Kirkland, Quebec, Valeo Pharma has the full capability and complete infrastructure to register and properly manage its growing product portfolio through all stages of commercialization. For more information, please visit and follow us on LinkedIn and Twitter.

Forward Looking Statements

This press release contains forward-looking statements about Valeo's objectives, strategies and businesses that involve risks and uncertainties. These statements are "forward-looking" because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate.

SOURCE Valeo Pharma Inc.

Cision View original content to download multimedia:

Copyright CNW Group 2022

Comment On!

Upload limit is up to 1mb only
To post messages to your Socail Media account, you must first give authorization from the websites. Select the platform you wish to connect your account to (via Easy Blurb).